Hims & Hers (HIMS) stock jumped 13% after FDA scheduled peptide review meetings. BofA raised price target to $25 amid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results